Emerging Deubiquitinase Target in Oncology: Market Intelligence, Assay Development, and High-Purity Enzymatic Reagents for Protein Homeostasis Research.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for JOSD2 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | JOSD2 Recombinant Protein (WT & C26A Mutant) High purity (>95%), Endotoxin <1EU/ug. Includes catalytic-dead Cys26Ala mutant for negative control assays. Sequence Verified. |
View JOSD2 Products |
| Gene Delivery | JOSD2 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. Codon-optimized for high expression in mammalian systems. |
View JOSD2 Products |
| Detection Ab | Anti-JOSD2 (Rabbit Monoclonal) High specificity for Western/IP. No cross-reactivity with JOSD1 or ATXN3. |
View JOSD2 Products |
| Validator | JOSD2 siRNA Set (3 unique sequences) For knockdown verification and target engagement confirmation. |
View JOSD2 Products |
| Related Target A | JOSD1 (Josephin Domain Containing 1) Closest paralog; essential for Josephin-family selectivity counter-screening. |
View JOSD1 Products |
| Related Target B | ATXN3 (Ataxin-3) Josephin domain family member; critical for selectivity profiling against homologous DUBs. |
View ATXN3 Products |
| Related Target C | CTNNB1 (Beta-catenin) Downstream oncogenic effector stabilized by JOSD2. |
View CTNNB1 Products |
| Related Target D | USP7 (HAUSP) Synergistic deubiquitinase in p53 pathway; functional overlap in cancer cell survival. |
View USP7 Products |
| Related Target E | OTUB1 Ovarian tumor domain DUB; distinct family for broad selectivity counter-screening. |
View OTUB1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Josephin Family Selectivity (JOSD1, ATXN3) | Homolog panel proteins (JOSD1, JOSD2, ATXN3) strictly verified by mass spec; >95% purity ensures clean SPR/DSF data |
| Catalytic Activity vs Binding Discrimination | WT/C26A paired protein set available; catalytic-dead mutant essential for artifact control in HTS |
| Cellular Target Engagement | Ubiquitin-rhodamine assay validated with sequence-verified enzymes; siRNA included for specificity confirmation |
| Compound Library Screening Stability | HEK293 expressed (native folding); endotoxin-controlled (<1 EU/µg) for sensitive enzymatic assays |
Live JOSD2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
- ➤ View Active Clinical Trials
- ➤ Latest Inhibitor Research
- ➤ Resistance Research
- ➤ Recent Patent Filings
Global Clinical Landscape & Future Outlook
The race for deubiquitinase (DUB) inhibitors is intensifying, with JOSD2 emerging as a high-value target in prostate, breast, and lung oncology. Unlike heavily pursued DUBs such as USP7 or USP1, JOSD2 represents a differentiated entry point into the ubiquitin-proteasome system. Preclinical data suggest synthetic lethality with AR signaling in prostate cancer, metabolic reprogramming in NSCLC, and stabilization of oncogenic drivers like beta-catenin. As first-generation DUB inhibitors enter Phase I, the next wave of R&D is targeting covalent reversible inhibitors, PROTAC-mediated degradation, and combination regimens with immuno-oncology standards. JOSD2's compact Josephin domain structure presents unique challenges for drug design, requiring highly specific biochemical tools to distinguish catalytic inhibition from non-specific cysteine reactivity.
Competitive Modality & Indication Snapshot
Connect market trends to assay needs.
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (Covalent/Non-covalent) | Progenra, Mission Therapeutics, Academic consortia, Biotech startups | Prostate Cancer, Breast Cancer, NSCLC, Melanoma | Enzymatic Activity Assay (Ub-Rhodamine); need WT/C26A mutant pair for specificity validation; high-purity protein (>95%) for accurate IC50 |
| PROTAC Degraders | Emerging programs, Targeted protein degradation platforms | Drug-Resistant Solid Tumors, Oncology | Ternary complex validation (pure JOSD2 + E3 ligase); cellular target engagement via lentivirus lines |
| RNAi / ASO | Undisclosed preclinical groups | Metabolic Disorders, Oncology | Knockdown verification (validated siRNA set and benchmark antibodies) |